Thirty-two healthy volunteer women (37.0±4.8 years) were allocated as follows: Group E-30 (n=11) were treated with
30 tablets/day of the study product (containing 7,125mg/day of dried brewer’s yeast), Group E-9 (n=10) were given 9 tablets/day
of the study product, and the control group (n=11) were given 30 placebo tablets/day. The treatment period was 8 weeks. Two
patients prematurely discontinued the study (discontinuation rate: 5.9%) and were excluded from the analyses. The study product
(Ebios Tablet®) was provided by Asahi Food & Healthcare Co., Ltd. Before and at 4 and 8 weeks after the study, subjective
symptoms were evaluated using the Anti-Aging QOL Common Questionnaire (AAQol) and checking skin symptoms, skin
images were analyzed with SK Info (SKI, Integral Co.) and Aphrodite-III (PSI), and skin color (CM-700d, Konica Minolta
Sensing, Inc.) and elasticity (Cutometer MPA580, Courage & Khazaka electronic GmbH) were measured.
Thirty-two healthy volunteer women (37.0±4.8 years) were allocated as follows: Group E-30 (n=11) were treated with30 tablets/day of the study product (containing 7,125mg/day of dried brewer’s yeast), Group E-9 (n=10) were given 9 tablets/dayof the study product, and the control group (n=11) were given 30 placebo tablets/day. The treatment period was 8 weeks. Twopatients prematurely discontinued the study (discontinuation rate: 5.9%) and were excluded from the analyses. The study product(Ebios Tablet®) was provided by Asahi Food & Healthcare Co., Ltd. Before and at 4 and 8 weeks after the study, subjectivesymptoms were evaluated using the Anti-Aging QOL Common Questionnaire (AAQol) and checking skin symptoms, skinimages were analyzed with SK Info (SKI, Integral Co.) and Aphrodite-III (PSI), and skin color (CM-700d, Konica MinoltaSensing, Inc.) and elasticity (Cutometer MPA580, Courage & Khazaka electronic GmbH) were measured.
การแปล กรุณารอสักครู่..